Hereditary breast cancer and ovarian cancer: clinical course and treatment

Abstract

This article analyzes current problems associated with surgical and systemic treatment for hereditary breast and ovarian cancers (including those associated with BRCA1/2 gene mutations). We discuss the issues related to clinical course of multiple primary tumors and their sensitivity to cytostatic and targeted therapy.

Keywords

• breast cancer
• ovarian cancer
• multiple primary tumors
• brca1
• brca2
• chek2
• parp inhibitors